| Title |
Update on optimal use of omalizumab in management of asthma
|
|---|---|
| Published in |
Journal of Asthma and Allergy, June 2011
|
| DOI | 10.2147/jaa.s14520 |
| Pubmed ID | |
| Authors |
Girolamo Pelaia, Luca Gallelli, Teresa Renda, Pasquale Romeo, Maria Teresa Busceti, Rosa Daniela Grembiale, Rosario Maselli, Serafino Antonio Marsico, Alessandro Vatrella |
| Abstract |
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 82 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 17% |
| Researcher | 13 | 15% |
| Student > Master | 9 | 11% |
| Student > Postgraduate | 7 | 8% |
| Student > Ph. D. Student | 6 | 7% |
| Other | 11 | 13% |
| Unknown | 24 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 35% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Agricultural and Biological Sciences | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Immunology and Microbiology | 3 | 4% |
| Other | 4 | 5% |
| Unknown | 27 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2012.
All research outputs
#17,286,379
of 25,374,647 outputs
Outputs from Journal of Asthma and Allergy
#371
of 543 outputs
Outputs of similar age
#91,777
of 122,185 outputs
Outputs of similar age from Journal of Asthma and Allergy
#2
of 2 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 543 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,185 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.